第一作者:
Li,Zhong
第一单位:
Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, P R China.
作者:
主题词
血管生成抑制剂(Angiogenesis Inhibitors);动物(Animals);细胞分化(Cell Differentiation);细胞系, 肿瘤(Cell Line, Tumor);细胞运动(Cell Movement);细胞增殖(Cell Proliferation);细胞存活(Cell Survival);鸡胚(Chick Embryo);绒毛尿囊膜(Chorioallantoic Membrane);内皮细胞(Endothelial Cells);酶抑制剂(Enzyme Inhibitors);人类(Humans);免疫印迹法(Immunoblotting);小鼠(Mice);NIH 3T3细胞(NIH 3T3 Cells);新生血管化, 生理性(Neovascularization, Physiologic);磷酰化(Phosphorylation);蛋白酪氨酸激酶类(Protein-Tyrosine Kinases);吡啶类(Pyridines);嘧啶酮类(Pyrimidinones);受体, 血小板源生长因子β(Receptor, Platelet-Derived Growth Factor beta);重组蛋白质类(Recombinant Proteins);信号传导(Signal Transduction);血管内皮生长因子受体2(Vascular Endothelial Growth Factor Receptor-2)
DOI
10.4161/cbt.5.3.2543
PMID
16575201
发布时间
2020-09-30
- 浏览4

Cancer biology & therapy
323-30页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文